Navigation Links
First Patient Enrolled in Lutonix Drug-Coated Balloon Pivotal Trial
Date:7/25/2011

MINNEAPOLIS, July 25, 2011 /PRNewswire/ -- Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD).  The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.

LEVANT 2 is the first drug-coated balloon IDE trial to be approved by the FDA, and is being conducted to support a PMA application for US approval of the company's Moxy balloon.  The trial is expected to randomize approximately 476 patients at up to 55 hospitals worldwide.  LEVANT 2 is the largest randomized peripheral drug-coated balloon trial to date, and one of the largest peripheral vascular studies ever conducted.

Randomized patients in LEVANT 2 will be followed for a total of 5 years and independent core laboratories will verify trial outcomes.  The primary safety endpoint is a composite of freedom from all-cause peri-operative death and freedom at 1 year from amputation, re-intervention and death.  The primary efficacy endpoint is primary patency at 1 year.  Dr. Kenneth Rosenfield (Massachusetts General Hospital, Boston MA) and Prof. Dierk Scheinert (Heart Center Leipzig/Park Hospital, Leipzig Germany) are the co-principal investigators of the trial.  

"We are very pleased to be the first center to contribute to such an important trial.  We believe drug-coated balloons may play an important role in the future of peripheral interventions, and we are proud to be involved in such a well-designed, carefully controlled trial to explore this promising new therapy," said Dr. Goldstein, site principal investigator at St. John's Hospital.

Co-investigator Dr. Krishna Rocha-Singh added, "With 8-12 million patients known to suffer from PAD and a paucity of durable, highly effective therapies, patients and physicians are in need of a game-changing treatment modality.  The LEVANT 2 trial will help us determine whether a drug-coated balloon can fill this gap."  

Drug-coated balloons have received growing attention in recent years as physicians increasingly look for effective ways to treat diseased leg arteries without having to leave a permanent stent implant behind.  Like the drug-eluting stents commonly used in the heart, the Moxy balloon delivers a powerful restenosis-fighting drug to the artery.  However, unlike a stent, the Moxy balloon is removed from the body after use, leaving nothing but the drug behind in the artery.  

Physician enthusiasm for the drug-coated balloon concept has been bolstered by encouraging results from early trials like LEVANT 1, a precedent study to LEVANT 2.  LEVANT 1 was a 101-patient randomized trial in which the Moxy balloon was compared to standard angioplasty for the treatment of diseased femoropopliteal arteries.  The trial showed the Moxy balloon had the ability to safely and substantially inhibit restenosis.

"There is tremendous enthusiasm within the medical community about the potential for drug-coated balloons to improve outcomes for our patients," explained Dr. Rosenfield.   "However, because the field is young, we need data from large, randomized controlled clinical trials that are independently validated.  Because of its scientific rigor, LEVANT 2 will help address this need.  On behalf of Dr. Scheinert and myself, we congratulate St. John's on their enrollment of the first patient in this landmark trial."

About the Moxy Drug Coated Balloon

The Moxy balloon is very similar to a standard angioplasty balloon, but is coated with an anti-restenotic drug designed to help keep arteries open and free from re-blockage.   During the procedure, the Moxy balloon is inflated for 30 seconds during which it opens up the artery to restore blood flow, and delivers the drug to the artery wall.  The Moxy balloon is then removed from the body leaving nothing behind but the drug coating, which works inside the artery over time to prevent restenosis.  The Moxy balloon is an investigational device, which is not approved for, or available for sale in, the United States.

About Restenosis

Restenosis refers to the re-narrowing of an artery following angioplasty or stenting.  Restenosis is caused by an overgrowth of tissue inside the artery, typically in response to injury caused at the original treatment site.  Restenosis often occurs within the first 6 months following an intervention, and most often results in re-treatment.

About Lutonix, Inc. (www.lutonix.com)

Lutonix is a venture-backed medical device company based in Minneapolis, MN.   The company is dedicated to the development and commercialization of a safe, efficacious drug-coated balloon for the treatment of coronary and peripheral vascular disease.   Current investors include Delphi Ventures, RiverVest Ventures, US Venture Partners, Versant Ventures, Warburg Pincus and The Vertical Group.


'/>"/>
SOURCE Lutonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mail-Order Pharmacy for New Statin Prescriptions Achieve Better Cholesterol Control in First 3-15 Months of Therapy
2. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
3. Berkery Noyes Releases First Half 2011 M&A Report for the Pharma and Healthcare Information and Technology Industry
4. First Advantage Invests in Workstream Inc.
5. Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardicas Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
6. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
7. Intelsius Forms Strategic Partnership With American Thermal Instruments to Launch Industrys First Fully Integrated Temperature-Controlled Packaging and Monitoring Solution
8. Dehaier Opens First Oxygen Filling Facility and First Service Center for Home Oxygen Therapy Service in Beijing
9. Kessler is the First Rehabilitation Center in the Nation to Use New Robotic Gait Training System
10. First Reportable Data of EarlyCDT™-Lung Use in Clinical Practice Presented at IASLC World Conference on Lung Cancer
11. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):